Bronchodilators Market Size, Share & Trends Analysis Report By Disease (Asthma, COPD), By Route Of Administration (Inhalable, Oral), By Drug Class (Beta-Adrenergic, Anticholinergics), By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global bronchodilators market size was exhibited at USD 22.25 billion in 2022 and is projected to hit around USD 30.22 billion by 2032, growing at a CAGR of 3.11% during the forecast period 2023 to 2032.

Key Pointers:

• The beta-adrenergic bronchodilators segment dominated the market in 2022 with the largest revenue share of more than 40.9% and is expected to expand at the fastest CAGR of 3.34% during the forecast period.
• The nasal (Inhalable) segment held the largest market share of 51.11% in 2022
• The asthma segment accounted for the largest revenue share of 41.15% in the market in 2022 and expanded at the fastest CAGR of 3.32% over the forecast period. 
• Oral segment is projected to grow at the fastest rate over the forecast period attributable to it being the second most preferred mode of administration amongst clinicians and patients
• North America dominated the market in 2022, which is attributed to the presence of key market players in the region, highly developed healthcare infrastructure, better affordability

 Bronchodilators Market Report Scope

The growth of the bronchodilators market is attributed to the increasing geriatric population and rising population with respiratory disorders. Moreover, respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma are more common among the elderly population.

The demand for bronchodilators is growing significantly, owing to the increasing incidence of respiratory disorders. The surging number of smokers is increasing the population with a heightened risk of lung conditions such as asthma and COPD. For instance, as per WHO in 2021, there are over 1.3 billion smokers globally with 80% of them situated in LMIC’s. This population has an accelerated rate of deterioration in lung function along with intensified mortality rate. As per American Lung Association, 17% of the population with asthma are smokers which is 13.7% in the non-asthmatic population. This creates a need for persistent use of bronchodilators in patients, thereby, accelerating the demand for bronchodilators.

Moreover, there are increasing efforts from public and private organizations to increase awareness among the population. International organizations such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) are working with public health officials and healthcare professionals worldwide to increase awareness and improve the treatment and prevention of COPD around the world. Moreover, companies such as AstraZeneca, Cipla, Teva, and several others have been trying to spread awareness through social media platforms such as ‘Get Real’, #Laugh4Lungs’, ‘Inhalers are Right for Asthma’, ‘Inhaler is boon for Asthma’, and many more. These campaigns help raise awareness and encourage patients towards using more bronchodilators and enable them to secure their lives by taking preventive measures. Furthermore, the market is expected to grow due to regional market players ongoing R&D efforts to develop an effective treatment for patients with respiratory disorders.

Companies are collaborating to develop novel treatments to address unmet medical needs. This enables businesses to use their resources to help with product development and supply chain improvements. Moreover, a number of players are also focusing on product launches in order to expand their product portfolio. For instance, in September 2021, AstraZeneca started working on a combination formulation of inhaled corticosteroid (ICS) budesonide and beta2-agonist (SABA) albuterol for the treatment of patients with Asthma, which if approved is expected to be the first ICS/SABA combo rescue inhaler for asthma in the U.S.

Bronchodilators Market Segmentation